Post-pandemic healthcare trends will turn, says SEB's new biotech portfolio lead
The life science industry has "pent-up demand" and could see a reversal in some segments' performances as the post-pandemic world starts to normalize, according to Sweden's SEB Investment Management, which has just switched approach to its healthcare and biotech funds after these were surpassed by their benchmarks. The new strategy seeks to better utilize investment opportunities within the sector.
BY REETA ILONA PAAKKINEN, AMWATCH
Some of the prevailing trends in healthcare and biotech funds during the Covid-19 pandemic will reverse as the economy opens up post-pandemic, says Angelica Fatouros, portfolio manager of healthcare and biotechnology funds at SEB Investment Management.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
